(Reuters) - GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness ...

GSK has won its latest trial over whether its former best-selling ... known as NDMA that had been found in GSK’s heartburn drug Zantac; also known as ranitidine. The decision is the latest ...

A month before it was set to take the stand in the highly anticipated first Zantac-related trial, GSK scratched ... Last month, GSK saw a win in a key class-action suit in Canada after the British ...

GSK and Boehringer Ingelheim are the only defendants in the trial, after other ... and does not contain ranitidine. The companies notched a significant win in 2022 when a judge dismissed about ...

GSK Plc convinced an Illinois jury that the former heartburn drug Zantac was not liable for a woman’s colorectal cancer in a second trial win for the British drugmaker. It comes just over two ...

UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid litigation over alleged cancer risks. The Florida State Court ruled in ...

GSK has won its latest trial over whether its former best-selling drug caused ... from a contaminant known as NDMA that had been found in GSK’s heartburn drug Zantac; also known as ranitidine. The ...